Concentration-Effect Relationship of /-Propranolol and Metoprolol in Spontaneous Hypertensive Rats after Exercise-Induced Tachycardia1

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 3, 1998, Pages 1152-1158

  Brynne, Lena ^a,b   Karlsson, Mats O ^a   Paalzow, Lennart K ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Division of Biopharmaceutics and Pharmacokinetics   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL TARTRATE; OROSOMUCOID; PROPRANOLOL; METOPROLOL; PLASMA PROTEIN;

ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARRHYTHMOGENESIS; ARTICLE; BIOLOGICAL MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MALE; MEMBRANE STABILIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; TACHYCARDIA; ANIMAL; ANIMAL EXPERIMENT; DOSE RESPONSE; HEART RATE; METABOLISM; PATHOPHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HYPERTENSION; MALE; METOPROLOL; PHYSICAL CONDITIONING, ANIMAL; PROPRANOLOL; PROTEIN BINDING; RATS; RATS, INBRED SHR;

EID: 0032158768     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ablad B, Carlsson E, Johansson and Regârdh C-G (1980) Metoprolol, in Pharmacology of Antihypertensive Drugs (Scriabine A ed) pp 247-262, Raven Press, New York.
2. Abrahamsson B, Lücker P, Olofsson B, Regârdh C-G, Sandberg A, Wieseigren I and Bergstrand R (1990) The relationship between metoprolol plasma concentration and betarblockade in healthy subjects: A study on conventional metoprolol and metoprolol CR/ZOK formulations. J Clin Pharmacol 30:S46-S54.
3. Arnold JMO, O'Connor PC, Riddell JG, Harron DWG, Shanks RG and McDevitt DC (1985) Effects of the β2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced β-adrenoceptor responses in man. Br J Clin Pharmacol 19:619-630.
4. Beal SL and Sheiner LB eds (1992) NONMEM Users Guides. NONMEM Project Group, University of California at San Francisco, San Francisco.
5. Brodde O-E, Karad K, Zerkowski H-R, Rohm N and Reidemeister JC (1983) Coexistence of βr and β2'aQ'renoceptors in human right atrium. Circ Res 53:752-758.
6. Brogden RN, Heel RC, Speight TM and Avery GS (1977) Metoprolol: A review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 14:321-348.
7. Chindavijak B, Belpaire FM, De Smet F and Bogaert MG (1988) Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat. J Pharmacol Exp Ther 246:1075-1079.
8. Evans GH, Nies AS and Shand DG (1973) The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther 186:114-122.
9. Gibaldi M and Ferner D (1982) Multicompartment models. Pharmacokinetics, 2nd ed pp 45-111, Marcel Dekker, Inc., New York.
10. Hager WD, Pieniaszek HJ, Ferner Jr BA, Mayersohn M and Goldberger V (1981) Assessment of beta blockade with propranolol. Clin Pharmacol Ther 30:283-290.
11. Harry JD, Norris SC, Percival GC and Young J (1988) The dose in humans at which ICI 188,551 (a selective β2-adrenoceptor blocking agent) demonstrates blockade of (3radrenoceptors. Clin Pharmacol Ther 43:492-498.
12. Huffman BB and Lefkowitz RJ (1996) Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists, in Goodman & Oilman's The Pharmacological Basis of Therapeutics, 9th ed (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Oilman AG eds) pp 199-248, McGraw-Hill, Inc., New York.
13. Holford NHG and Sheiner LB (1982) Kinetics of pharmacologie response. Pharmacol Ther 16:143-166.
14. Imamura H, Maruyama T, Okabe H, Shimada H and Otagiri M (1994) A simple and rapid fluorometric determination method of aracid glycoprotein in serum using quinaldine red. Pharm Res 11:566-570.
15. Jonsson EN and Karlsson MO (1998) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comp Methods Prog Med, in press.
16. Lalonde RL, Straka RJ, Pieper JA, Bottorff MB and Mirvis DM (1987) Propranolol pharmacodynamic modeling using unbound and total concentrations in health y volunteers. J Pharmacokin Biopharm 15:569-582.
17. Lin T-H, Sugiyama Y, Sawada Y, Suzuki Y, Iga T and Hanano M (1987) Effect of surgery on serum j-acid glycoprotein concentration and serum protein binding of d/-propranolol in phenobarbital-treated and untreated rats. Drug Metab Dispos 15:138-140.
18. Lipworth BJ, Irvine NA and McDevitt DG (1991) A dose-ranging study to evaluate the βradrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol 40:135-139.
19. Molenaar P and Summers RJ (1987) Characterization of beta-1 and beta-2 adrenoceptors in guinea pig atrium: Functional and receptor binding studies. J Pharmc.col Exp Ther 241:1041-1047.
20. Murray KT, Reilly C, Koshakji RP, Roden DM, Lineberry MD, Wood AJJ, Siddoway LA, Barbey JT and Woosely RL (1990) Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest 85:836-842.
21. Paalzow LK (1990) Pharmacodynamics, in Comprehensive Medical Chemistry, Biopharmaceutics (Mansch C, Sammes PG and Taylor JB eds) pp 333-358, Pergamon Press, Oxford.
22. Paalzow LK and Edlund PO (1979) Multiple receptor responses: A new concept to describe the relationship between pharmacological effects and pharmacokinetics of a drug: Studies on clonidine in the rat and cat. J Pharmacokin Biopharm 7:495 510.
23. Pringle TH, Riddell JG and Shanks RG (1988) Characterization of the betaadrenoceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol 35:507-514.
24. Pruett JK, Walle T arid Bagwell EE (1977) Association of in vivo and in vitro propranolol levels in canine Purkinje fibers with antiarrhythmic effects. J Pharmacol Exp Ther 202:45-54.
25. Pruett JK, Walle T and Walle UK (1980) Propranolol effects on membrane repolarization time in isolated canine Purkinje fibers: Threshold tissue content and the influence of exposure time. J Pharmacol Exp Ther 215:539-543.
26. Roden DM (1996) Antiarrhythmic drugs, in Goodman & Oilman's The Pharmacological Basis of Therapeutics, 9th ed (Hardman JG, Limbird LE, Molinoff PE., Ruddon RW, Gilman AG eds) pp 839-874, McGraw-Hill, Inc., New York.
27. Rutledge RD and Garrick C (1989) Determination of metoprolol and its a-hydroxida metabolite in serum by reversed-phase high-performance liquid Chromatograph}. J Chromatogr Sei 27:561-565.
28. Smits JFM and Struyker-Boudier HAJ (1979) Propranolol in conscious spontaneously hypertensive rats. II. Disposition after subcutaneous and intracerebroventricular administration. Naunyn-Schmiedeberg Arch Pharmacol 309:19-24.
29. Sowinski KM, Burlew BS and Johnson JA (1995) Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy men. Clin Pharmacol Ther 57:678-683.
30. Statistical Sciences Inc. (1993) S-PLUS Reference Manual, version 3.3. StatSci, a division of Mathsoft Inc., Seattle, WA.
31. Terao N and Shen DD 11983) Alterations in serum protein binding and pharmacokinetics of/-propranolol in the rat elicited by the presence of an indwelling venom catheter. J Pharmacol Exp Ther 227:369-375.
32. Vago T, Bevilacqua M, Dagani R, Meroni R, Frigeni G, Santoliβ C and Norbiato (J (1984) Comparison of rat and human left ventricle beta-adrenergic receptors: Subtype heterogeneity delineated by direct radioligand binding. Biochem Biophy.i Res Comm 121:346-354.
33. Vermeulen AM, Belpaire FM, De Smet F, Vercruysse I and Bogaert MG (1993) Aging and the pharmacokinetics and metabolism of metoprolol enantiomers in the rat. J Gerontology 48:B108-B114.
34. Wagner JG (1974) A safe method for rapidly achieving plasma concentration plateaus. Clin Pharmacol Ther 16:691-700.
35. Walle T, Webb JG, Bagwell EE, Walle UK, Daniell HB and Gaffney TE (1988I Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol 37:115-124.
36. Wellstein A, Palm D, Pitschner HF and Beiz GG (1985) Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Pharmacol 29:131-147.
37. Wellstein A, Woosley RL and Schwartz SL ( 1992) Antiarrhythmic drugs and cardiac glycosides, in The In Vivo Study of Drug Action (van Boxtel CJ, Holford NHG. Danhof M eds) pp 277-301, Elsevier Science Publishers B. V., Amsterdam.
38. Woosley RL, Kornhauser D, Smith R, Reele S, Higgins SB, Nies AS, Shand DG and Gates JA (1979) Suppression of chronic ventricular arrhythmias with propranolol Circulation 60:819-827.
39. Yasuhara M, Fujiwara J, Kitade S, Katayama H, Okumura K and Hori R (1983.1 Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: Role of aracid glycoprotein. J Pharmacol Exp Ther 235:513-520.